Literature DB >> 17028860

A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection.

Haruko Ideguchi1, Shigeru Ohno, Yoshiaki Ishigatsubo.   

Abstract

Human parvovirus B19 (B19) rarely induces pure red cell aplasia (PRCA) in healthy hosts. Meanwhile B19 infection is often clinically similar to systemic lupus erythematosus (SLE), and several cases have been reported wherein B19 actually stimulated SLE exacerbation in an immunocompetent subject. An 82-year-old healthy woman was diagnosed to have complicated with B19 infection and PRCA. Four weeks later, she had high fever, polyarthritis, and oral ulcers, additionally diagnosed with SLE, and subsequently, 15 mg of prednisone was started. This is the first case wherein B19 infection caused both PRCA and SLE in a healthy patient as far as our investigations are concerned.

Entities:  

Mesh:

Year:  2006        PMID: 17028860     DOI: 10.1007/s00296-006-0227-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

Review 1.  Acquired pure red cell aplasia.

Authors:  S S Ammus; A A Yunis
Journal:  Am J Hematol       Date:  1987-03       Impact factor: 10.047

2.  Chronic bone marrow failure due to persistent B19 parvovirus infection.

Authors:  G J Kurtzman; K Ozawa; B Cohen; G Hanson; R Oseas; N S Young
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

3.  [A case of systemic lupus erythematosus with pure red cell aplasia possibly caused by persistent infection of human parvovirus B 19].

Authors:  H Mitsunaka; M Tokuda; J Takahara; K Matoba; S Miyawaki
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  1998-12

Review 4.  Pure red-cell aplasia.

Authors:  S B Krantz
Journal:  N Engl J Med       Date:  1974-08-15       Impact factor: 91.245

Review 5.  Congenital hypoplastic anemia.

Authors:  L K Diamond; W C Wang; B P Alter
Journal:  Adv Pediatr       Date:  1976

6.  Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid.

Authors:  Alice Y K Chan; Edmund K Li; L S Tam; Gregory Cheng; Paul C L Choi
Journal:  Rheumatol Int       Date:  2004-11-25       Impact factor: 2.631

7.  Human parvovirus B19 infection during the inactive stage of systemic lupus erythematosus.

Authors:  Takashiro Suzuki; Shinichiro Saito; Yasuhiko Hirabayashi; Hideo Harigae; Tomonori Ishii; Takao Kodera; Hiroshi Fujii; Yasuhiko Munakata; Takeshi Sasaki
Journal:  Intern Med       Date:  2003-06       Impact factor: 1.271

8.  Parvovirus-like particles in human sera.

Authors:  Y E Cossart; A M Field; B Cant; D Widdows
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

Review 9.  Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A.

Authors:  F Atzeni; P Sarzi-Puttini; F Capsoni; L Vulpio; M Carrabba
Journal:  Clin Exp Rheumatol       Date:  2003 Nov-Dec       Impact factor: 4.473

Review 10.  Parvovirus B19 and autoimmune diseases.

Authors:  Olivier Meyer
Journal:  Joint Bone Spine       Date:  2003-02       Impact factor: 4.929

View more
  4 in total

1.  Parvovirus b19 infections and blood counts in blood donors.

Authors:  David Juhl; Dagmar Steppat; Siegfried Görg; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

Review 2.  The initial presentation of systemic lupus erythematosis with aplastic anemia successfully treated with rituximab.

Authors:  Gholam-Hossein Alishiri; Amin Saburi; Noushin Bayat; Ali-Reza Saadat; Ehsan Saburi
Journal:  Clin Rheumatol       Date:  2011-10-21       Impact factor: 2.980

3.  Detection of Parvovirus B19 Infection in Thalasemic Patients in Isfahan Province, Iran.

Authors:  Razieh Nikoozad; Mohammad Reza Mahzounieh; Mohammad Reza Ghorani
Journal:  Jundishapur J Microbiol       Date:  2015-11-08       Impact factor: 0.747

Review 4.  Parvovirus B19: What Is the Relevance in Transfusion Medicine?

Authors:  David Juhl; Holger Hennig
Journal:  Front Med (Lausanne)       Date:  2018-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.